Nivolumab‐induced acute tubular injury: A case report

Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs‐induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58‐year‐old woman had gastric cancer treated with nivolumab. Her serum creatinine (Cr) increased to 5.94 mg/dL post 2 cycles of nivolumab and co‐admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui‐Hsin, Chang, Chia‐Wen, Chen, Tai‐Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992483/
https://www.ncbi.nlm.nih.gov/pubmed/36911644
http://dx.doi.org/10.1002/ccr3.6991
_version_ 1784902319122415616
author Yang, Hui‐Hsin
Chang, Chia‐Wen
Chen, Tai‐Di
author_facet Yang, Hui‐Hsin
Chang, Chia‐Wen
Chen, Tai‐Di
author_sort Yang, Hui‐Hsin
collection PubMed
description Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs‐induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58‐year‐old woman had gastric cancer treated with nivolumab. Her serum creatinine (Cr) increased to 5.94 mg/dL post 2 cycles of nivolumab and co‐administered with acemetacin. A kidney biopsy showed acute tubular injury (ATI). Nivolumab rechallenge was done and Cr worsened again. The lymphocyte transformation test (LTT) indicated a strong positive for nivolumab. Although rare, ATI due to ICIs could not be ruled out, and LTT is a tool to identify the culprit.
format Online
Article
Text
id pubmed-9992483
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99924832023-03-09 Nivolumab‐induced acute tubular injury: A case report Yang, Hui‐Hsin Chang, Chia‐Wen Chen, Tai‐Di Clin Case Rep Case Report Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs‐induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58‐year‐old woman had gastric cancer treated with nivolumab. Her serum creatinine (Cr) increased to 5.94 mg/dL post 2 cycles of nivolumab and co‐administered with acemetacin. A kidney biopsy showed acute tubular injury (ATI). Nivolumab rechallenge was done and Cr worsened again. The lymphocyte transformation test (LTT) indicated a strong positive for nivolumab. Although rare, ATI due to ICIs could not be ruled out, and LTT is a tool to identify the culprit. John Wiley and Sons Inc. 2023-03-07 /pmc/articles/PMC9992483/ /pubmed/36911644 http://dx.doi.org/10.1002/ccr3.6991 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Yang, Hui‐Hsin
Chang, Chia‐Wen
Chen, Tai‐Di
Nivolumab‐induced acute tubular injury: A case report
title Nivolumab‐induced acute tubular injury: A case report
title_full Nivolumab‐induced acute tubular injury: A case report
title_fullStr Nivolumab‐induced acute tubular injury: A case report
title_full_unstemmed Nivolumab‐induced acute tubular injury: A case report
title_short Nivolumab‐induced acute tubular injury: A case report
title_sort nivolumab‐induced acute tubular injury: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992483/
https://www.ncbi.nlm.nih.gov/pubmed/36911644
http://dx.doi.org/10.1002/ccr3.6991
work_keys_str_mv AT yanghuihsin nivolumabinducedacutetubularinjuryacasereport
AT changchiawen nivolumabinducedacutetubularinjuryacasereport
AT chentaidi nivolumabinducedacutetubularinjuryacasereport

Ejemplares similares